Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval

Michele B. Kaufman, PharmD, BCGP  |  September 27, 2016

GENERIC_Drugs_500x270Friday, Sept. 23, will be another day marked in history for those treating autoimmune diseases. The FDA has approved adalimumab-atto, also known as Amjevita, which is a biosimilar to adalimumab (Humira).1 Adalimumab-atto has received approval only for the following indications of the innovator product:

  • In adult patients with:
    —Moderate to severe active rheumatoid arthritis
    —Active psoriatic arthritis;
    —Active ankylosing spondylitis;
    —Moderate to severe active Crohn’s disease;
    —Moderate to severe active ulcerative colitis; and
    —Moderate to severe plaque psoriasis; as well as
  • In patients ages 4 years and older with:
    —moderate to severe active polyarticular juvenile idiopathic arthritis.

The approval of adalimumab-atto was based on a review of evidence, including structural and functional characterization, animal studies, human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrated its biosimilarity to the reference product, adalimumab. Adalimumab-atto has not been approved for all indications of the reference product, and interchangeability has not yet been determined. All dosing, administration, warnings and precautions, contraindications and boxed warnings of adalimumab-atto (Amjevita) match those of adalimumab (Humira).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although the treatment is FDA approved, the availability of adalimumab-atto will be delayed due to a required 180-day notice period that would result in, at earliest, a March 2017 launch of the treatment. AbbVie, the maker of adalimumab (Humira), has sued Amgen for patent infringement for its 10 indications. AbbVie has asked the court to block Amgen’s drug if and when the FDA issues an approval.2 Time will tell.


Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. U.S. Food and Drug Administration. News release: FDA approves Amjevita, a biosimilar to Humira. 2016 Sep 24
  2. Staton T. Amgen’s Humira biosim, Amjevita, passes FDA milestone on long road to market. FiercePharma, 2016 Sep 23.

Share: 

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabadalimumab-attoBiosimilarsFDAFood and Drug Administration

Related Articles

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    FDA Approves First Interchangeable Biosimilar to Adalimumab, Plus a Combination Drug Approved

    November 17, 2021

    Cyltezo (adalimumab-adbm) may be interchanged for Humira (adalimumab) for all indications, according to an October decison by the FDA. The FDA has also approved a new combination of celecoxib and tramadol for pain management.

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    paulista/shutterstock.com The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to…

    First Biosimilar to Adalimumab (Humira) Enters the U.S. Market After Years of Legal Battles

    January 31, 2023

    After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences